SCHEDULE 13G/A: BlackRock Adjusts Cidara Therapeutics Stake Below 5%

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.6% in Cidara Therapeutics, Inc. common stock.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in Cidara Therapeutics, Inc. common stock.
• As of the event date, BlackRock, Inc. beneficially owned an aggregate of 1,163,607 shares of common stock.
• This aggregate amount represents 4.6% of the class of securities.
• BlackRock, Inc. holds sole voting power over 1,130,519 shares and sole dispositive power over 1,163,607 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• BlackRock's beneficial ownership is now below the 5% threshold that typically triggers initial Schedule 13G filings.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of institutional ownership, indicating a reduction in BlackRock's stake below 5%. This is a factual compliance update and does not inherently convey strong positive or negative sentiment regarding the issuer's operational performance or future prospects.

Positives

• BlackRock, a prominent institutional investor, continues to hold a substantial stake in Cidara Therapeutics, indicating ongoing investment interest.

Negatives

• BlackRock's beneficial ownership has decreased to 4.6%, falling below the 5% threshold that initially triggered the Schedule 13G filing, which could signal a re-evaluation of the investment or portfolio rebalancing.

Risks

• The filing does not detail specific risks for Cidara Therapeutics, but BlackRock certifies that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Cidara Therapeutics, Inc.'s business or financial performance. It solely pertains to BlackRock, Inc.'s beneficial ownership position and intent.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This is a routine institutional ownership disclosure, reflecting a major asset manager's adjusted stake in a publicly traded company. Such filings are standard compliance requirements when an institutional investor's beneficial ownership crosses certain thresholds.

Stakeholder Impact

• Shareholders of Cidara Therapeutics, Inc. are informed of the adjusted beneficial ownership stake held by a significant institutional investor, BlackRock, Inc.

Next Steps

• BlackRock, Inc. will continue to comply with SEC reporting requirements for its beneficial ownership in Cidara Therapeutics, Inc.

Key Dates

Keywords

Cidara Therapeutics, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, Investment, Beneficial Ownership